(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr7.88 | 3.46% | 61.1% |
| CEGEDIM (CGM.PA) | €19.30 | 2.25% | 3.08% |
| LUMIBIRD (LBIRD.PA) | €13.12 | 1.25% | 5.68% |
| SARTORIUS STED BIO (DIM.PA) | €202.00 | 0.71% | 18.66% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.48.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 16.42. Meaning, the purchaser of the share is investing kr16.42 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
More news about CONTEXTVISION.
2. CEGEDIM (CGM.PA)
2.25% Forward Dividend Yield and 3.08% Return On Equity
Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals in France, other European countries, and internationally. It operates in two segments, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services segment markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This segment also provides solutions for hosting, HR and payroll management outsourcing, electronic data exchange, and data processing services. The Healthcare Professionals division sells management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €0.8.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 24.12. Meaning, the purchaser of the share is investing €24.12 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.08%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 29, 2022, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.25%.
Volume
Today’s last reported volume for CEGEDIM is 2237 which is 61.98% below its average volume of 5884.
Moving Average
CEGEDIM’s value is above its 50-day moving average of €18.13 and higher than its 200-day moving average of €19.25.
Yearly Top and Bottom Value
CEGEDIM’s stock is valued at €19.30 at 16:30 EST, way below its 52-week high of €23.55 and way higher than its 52-week low of €13.56.
More news about CEGEDIM.
3. LUMIBIRD (LBIRD.PA)
1.25% Forward Dividend Yield and 5.68% Return On Equity
Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two segments, Photonics and Medical. The company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, Laser rangefinder and LiDAR wind doppler LiDAR, medical and ophthalmological equipment. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The company was incorporated in 1970 and is headquartered in Lannion, France.
Earnings Per Share
As for profitability, LUMIBIRD has a trailing twelve months EPS of €0.45.
PE Ratio
LUMIBIRD has a trailing twelve months price to earnings ratio of 29.16. Meaning, the purchaser of the share is investing €29.16 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.68%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 206.53M for the twelve trailing months.
Volume
Today’s last reported volume for LUMIBIRD is 2438 which is 43.51% below its average volume of 4316.
More news about LUMIBIRD.
4. SARTORIUS STED BIO (DIM.PA)
0.71% Forward Dividend Yield and 18.66% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €6.89.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 29.32. Meaning, the purchaser of the share is investing €29.32 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.66%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SARTORIUS STED BIO’s stock is considered to be oversold (<=20).
Moving Average
SARTORIUS STED BIO’s worth is under its 50-day moving average of €202.55 and way under its 200-day moving average of €251.70.
Revenue Growth
Year-on-year quarterly revenue growth declined by 24.1%, now sitting on 2.96B for the twelve trailing months.
More news about SARTORIUS STED BIO.
